FGFR1 and neoplasm: The abnormal activation of FGFR1 is mainly associated with its genetic amplification, mutations, fusions, and rearrangements and is generally associated with high tumor aggressiveness, resistance to hormone therapy, poor differentiation, and adverse clinical outcomes.